Menu   WellSpan Health

Health Library

Health Library

Study of Tamoxifen and Raloxifene (STAR)

The Study of Tamoxifen and Raloxifene, or STAR, was a clinical trial that began at an estimated 500 sites across the United States, Puerto Rico, and Canada early in 1999. Participants in STAR included more than 19,000 postmenopausal women who were at increased risk for breast cancer. They were given a drug that could reduce their chances of developing breast cancer.

STAR built on the success of the Breast Cancer Prevention Trial, which showed that high-risk women taking the drug tamoxifen for an average of 4 years had a 49% reduced chance of developing breast cancer.

STAR was designed to help determine whether raloxifene (Evista), a drug similar to tamoxifen, was as effective as tamoxifen in reducing the chance of developing breast cancer in women who have not had the disease, and whether the drug had benefits over tamoxifen, such as fewer side effects. Raloxifene was first approved by the FDA as an osteoporosis prevention drug for postmenopausal women.

Study results showed that both tamoxifen and raloxifene lowered the risk of developing invasive breast cancer by about 50%. Also, the women who took raloxifene daily and were followed for around 4 years had 36% fewer uterine cancers and 29% fewer blood clots than the women who were on tamoxifen.

Women chosen to participate in STAR were age 35 or older, postmenopausal, and had an increased risk of breast cancer as determined by their age, family history of breast cancer, personal medical history, age at first menstrual period, and age at first live birth. They were randomly assigned to receive either tamoxifen daily or raloxifene daily for 5 years. They received close follow-up examinations, including mammograms, physical examinations, and gynecologic examinations, on a regular basis for at least 7 years.

Researchers with the National Surgical Adjuvant Breast and Bowel Project conducted the trial, which was funded by the National Cancer Institute. They selected the institutions to participate in STAR, including sites in 48 states, 6 Canadian provinces, the District of Columbia, and Puerto Rico.

STAR began enrolling participants in 1999 and completed enrollment in 2004. The trial concluded in 2006. The results of the STAR trial showed that regular use of raloxifene works as well as tamoxifen at reducing breast cancer risk in postmenopausal women who are at high risk, but appears less likely to cause some of the potentially dangerous side effects seen with tamoxifen use, such as an increase in uterine cancer and blood clots in the lungs and major veins.

Study of Tamoxifen and Raloxifene (STAR) - WellSpan Health

Online Medical Reviewer: Kolbus, Karin, RN, DNP, COHN-S
Online Medical Reviewer: MMI board-certified, academically affiliated clinician
Last Review Date: 2013-10-01T00:00:00
Last Modified Date: 2013-10-06T00:00:00
Posting Date: 2008-11-30T00:00:00
Published Date: 2013-10-06T00:00:00
Last Review Date: 2007-03-30T00:00:00
© 2015 WellSpan Health. All Rights Reserved. This information is not intended as a substitute for professional medical care. Always follow your healthcare professional's instructions.

I would like to:

Are you sure you would like to cancel?

All information will be lost.

Yes No ×

About the provider search

This search will provide you with WellSpan Medical Group and Northern Lancaster County (Ephrata) Medical Group primary care physicians and specialists. If we don’t have a WellSpan Medical Group physician to meet your criteria, the search will expand to include community physicians who partner with WellSpan Medical Group physicians through the WellSpan Provider Network or provide care to patients on the Medical Staffs of WellSpan’s Hospitals.


Schedule Your Next Appointment Online with MyWellSpan

Use your MyWellSpan patient portal any time to view available appointments, and pick the date and time that best suits your schedule.

Go to MyWellSpan

New to this practice?

If you don't have a WellSpan primary care provider and would like to schedule a new patient appointment with a provider who is accepting patients, just log into your MyWellSpan account, and go to the Appointment Center section. As you progress through the scheduling process, you will be able to see the offices that are accepting new patients in relation to your zip code. If you are not enrolled in MyWellSpan, go to, call 1-866-638-1842 or speak with a member of the staff at a participating facility to sign up. New patient scheduling not available at all practices/programs.

Already a patient at this practice?

If you already have a relationship with a WellSpan practice, simply log into your account, and go to the Appointment Center section. As you progress through the scheduling process, you will be able to schedule an appointment with any provider or practice that already counts you as a patient. Online scheduling varies by practice/program.